Loading clinical trials...
Loading clinical trials...
A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily
Conditions
Interventions
once daily minimum 3-drug regimen of anti-retroviral medications
Locations
1
Australia
407 Doctors
Sydney, New South Wales, Australia
Start Date
May 1, 2004
Last Updated
October 25, 2005
NCT04929028
NCT06694805
NCT04142047
NCT06741631
NCT07428330
NCT06741618
Lead Sponsor
407 Doctors
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions